Robeco Institutional Asset Management B.V. Purchases 25,183 Shares of Johnson & Johnson $JNJ

Robeco Institutional Asset Management B.V. grew its position in Johnson & Johnson (NYSE:JNJ) by 1.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,805,207 shares of the company’s stock after acquiring an additional 25,183 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.08% of Johnson & Johnson worth $275,745,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Clarity Financial LLC increased its position in Johnson & Johnson by 4.5% in the second quarter. Clarity Financial LLC now owns 2,170 shares of the company’s stock worth $331,000 after purchasing an additional 94 shares during the last quarter. Woodward Diversified Capital LLC increased its holdings in shares of Johnson & Johnson by 25.2% in the 2nd quarter. Woodward Diversified Capital LLC now owns 16,470 shares of the company’s stock worth $2,516,000 after buying an additional 3,311 shares during the last quarter. BOCHK Asset Management Ltd purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $153,000. Precision Wealth Strategies LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $826,000. Finally, USA Financial Formulas grew its position in Johnson & Johnson by 19.2% in the second quarter. USA Financial Formulas now owns 1,709 shares of the company’s stock worth $261,000 after acquiring an additional 275 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 1.4%

Shares of NYSE JNJ opened at $188.51 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $189.78. The stock’s fifty day simple moving average is $176.18 and its two-hundred day simple moving average is $162.83. The stock has a market capitalization of $453.98 billion, a PE ratio of 20.16, a price-to-earnings-growth ratio of 2.37 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same period in the prior year, the business posted $2.82 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Analysts Set New Price Targets

Several research firms have recently issued reports on JNJ. Bank of America raised their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research note on Friday. Morgan Stanley raised their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Citigroup boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, August 21st. The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a research note on Friday, September 19th. Finally, Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $187.47.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.